Compare Adaptive Biotechnologies Corp (ADPT) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CSX Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.05 (market cap $3.33B), while CSX Corporation trades at $48.17 (market cap $90.14B). The key difference: CSX Corporation is far larger — about 27.1× Adaptive Biotechnologies Corp's market cap, and CSX Corporation pays a 1.15% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CSX | |
|---|---|---|
Market Cap | $3.33B | $90.14B |
Sector | Health | Industrials |
52-Week High | $22.37 | $48.89 |
52-Week Low | $10.24 | $32.05 |
Enterprise Value | $3.19B | $108.37B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CSX trades at $48.51, down 0.78% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The company reported a net income margin of 21.55% for 2025, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analyst consensus is a Buy with a $46.83 price target, and the stock has seen positive news coverage highlighting operational improvements and a recent dividend declaration.
The outlook for CSX is cautiously optimistic, supported by strong profitability metrics and analyst upgrades, but tempered by declining revenue trends and high valuation multiples. Key risks include freight demand volatility and competitive pressures, while institutional sentiment remains positive with a majority of analysts recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
